Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial

Cancer

Volumn 91, Issue 11, 2001, Pages 2010-2015

  Loehrer Sr , Patrick J ^a,g   Jiroutek, Michael ^b   Aisner, Seena ^c   Aisner, Joseph ^c   Green, Mark ^d   Thomas Jr , Charles R ^d   Livingston, Robert ^e   Johnson, David H ^f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g Indiana Cancer Pavilion   (United States)

Author keywords

Cisplatin; Etoposide; Ifosfamide; Thymic carcinoma; Thymoma

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THYMOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THYMOMA; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 0342468002     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2     Document Type: Article

References (24)

1. Mullen B, Richardson JD. Primary anterior mediastinal tumors in children and adults. Ann Thorac Surg 1986;42:338-45.
2. Loehrer PJ. Thymomas: current experience and future directions in therapy. Drugs 1993;45:477-87.
3. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 Phase II trial of cisplatin n metastatic or recurrent thymoma. Am J Clin Oncol 1993;16:342-5.
4. Boston B. Chemotherapy of invasive thymoma. Cancer 1976; 38:59-2.
5. Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999;17:2737-44.
6. LaRocca R, Cooper M, Danesi R, et al. Suramin therapy for malignant thymoma: a case report. Eur J Cancer 1994;30(A Suppl):718-71.
7. Fornaserio A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma: a 13 year experience. Cancer 1998;68: 30-3.
8. Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, Bevilacqua G, et al. Neoadjuvant chemotherapy, surgery and postoperative radiation therapy for invasive thymoma. Cancer 1991; 68:706-13.
9. Shin DM, Walsh GL, Komaki R, Putnam JB, Nesbitt J, Ro JY, et al. Induction chemotherapy (IC) followed by surgical resection (SR), radiotherapy and consolidative chemotherapy may cure the advanced stages of unresectable invasive thymoma. Ann Intern Med 1998;129:100-4.
10. Lara PN, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin and cyclophosphamide. Chest 1996;110:1115-7.
11. Loehrer PJ, Kim KM, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol 1994;12:1164-8.
12. Loehrer PJ, Chen M, Kim KM, Aisner SC, Einhorn LH, Livingston R, et al. Cisplatin, doxorubicin and cyclophosphamide plus thoracic radiation therapy for limited stage, unresectable thymoma: an intergroup trial. J Clin Oncol 1997; 15:3093-9.
13. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a Phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1991;14:814-20.
14. Rea F, Sartori F, Lay M, et al. Chemotherapy and operation for invasive thymoma. J Cardiovasc Surg 1993;106:543.
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6):649-55.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Woolson RF. Statistical methods for the analyses of biomedical data. New York: John Wiley & Sons, 1987:125.
18. Suster S, Rosai J. Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991;67:1025-32.
19. Koh WJ, Loehrer PJ Sr., Thomas CR Jr. Thymoma: the role of radiation and chemotherapy. In: Wood DE, Thomas CR Jr., editors. Mediastinal tumors: update 1995. Medical radiology-diagnostic imaging and radiation oncology. Heidelberg: Springer-Verlag, 1995:19-5.
20. Wick MR. Mediastinum. In: Sternberg SS, editor. Diagnostic surgical pathology. 2nd ed, vol 1. New York: Raven Press, 1994:1125-82.
21. Marino M, Muller-Hermelink HK. Thymoma and thymic carcinoma: relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Arch (A) (Pathol Anat) 1985;407:117-49.
22. Hino N, Kondo K, Miyoshi T, Uyama T, Monden Y. High frequency of p53 protein expression in thymic carcinoma but not thymoma. Br J Cancer 1997;76(10 Suppl):1361-6.
23. Chen FF, Yan JJ, Jin YT, Su IJ. Detection of bcl-2 and p53 in thymoma: Expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol 1996;27(1 Suppl):1089-92.
24. Hirabayashi H, Fugii Y, Sakaguchi M, Tanaka H, Yoon HE, Komoto Y, et al. p16INK4, pRB, p43 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997;73(5 Suppl):639-44.